Orapi S.A. Stocks

6.5Last Updated 17.12.2024

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

€ 49.00M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
6.5
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Orapi SA, together with its subsidiaries, designs, manufactures, and sells products and solutions for hygiene and industrial maintenance worldwide. The company's products consist of cleaners, such as degreasers, disinfectants, hygiene and decontamination products, wiping pads, soaps, etc.; and lubricants, include greases and oils; and glues and adhesives, such as cyanoacrylates, anaerobes, and neoprenes. It also offers various wadding products, which include toilet papers and hand towels; waste bags; and personal protective equipment, such as gloves, masks, etc. The company operates under the Hexotol, Orapi Process, Orapi Hygiène, Proven, Orapi Technic, and Transnet brands. It serves customers in various sectors, such as industry, transport, leisure, collectivities, and health. The company was founded in 1968 and is based in Saint-Vulbas, France.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks